Julia is a Managing Partner at Breakout Ventures, investing at the intersection of technology, biology and chemistry and leveraging the rapid introduction of emerging technologies to effect change in high value markets. Julia has spent her career as an investor and operator, navigating the translation of new technologies in life sciences to customer adoption and scale. She has worked with multiple companies from founding through IPO or M&A and currently serves on the boards of Checkerspot and Immusoft. Julia trained as a research analyst on Wall Street and is also a Kaufman Fellow. She is a graduate of the University of Virginia, where she studied Finance and Bioethics.
Associate Director, Stanford University; Director, Business Development & Strategy, TriVascular Inc.; Associate, Investment Team, Kearny Venture Partners; Associate, Equity Research, Thomas Weisel Partners
Matt is Chief Executive Officer and co-founder of Oisín Bio. A serial entrepreneur with a background in computer security and immunology, Matt is also the founder and CEO of Immusoft, a biotech firm developing a breakthrough technology that will turn a patient's B cells into miniature drug factories. Matthew speaks and presents regularly to university, association and scientific audiences, including those at his alma mater, the University of Washington. He served for several years as a mentor to recipients of the Thiel Fellowship, a program that awarded grants to some of the world’s brightest scientific minds under age 20.